Related Experiment Video
Updated: Aug 29, 2025
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells
Agathe Reigstad1, Christina Frantzen Herdlevær1, Emma Rigg1
1Department of Biomedicine, University of Bergen, Bergen, Norway.
Abstract:
Melanomas frequently metastasize to the brain. Despite recent progress in the treatment of melanoma brain metastasis, therapy resistance and relapse of disease remain unsolved challenges. CCT196969 is a SRC family kinase (SFK) and Raf proto-oncogene, serine/threonine kinase (RAF) inhibitor with documented effects in primary melanoma cell lines in vitro and in vivo. Using in vitro cell line assays, we studied the effects of CCT196969 in multiple melanoma brain metastasis cell lines. The drug effectively inhibited proliferation, migration, and survival in all examined cell lines, with viability IC50 doses in the range of 0.18-2.6 μM. Western blot analysis showed decreased expression of p-ERK, p-MEK, p-STAT3 and STAT3 upon CCT196969 treatment. Furthermore, CCT196969 inhibited viability in two B-Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis.
Insights
CCT196969, a dual SRC family kinase (SFK) and Raf proto-oncogene, serine/threonine kinase (RAF) inhibitor, effectively reduced melanoma brain metastasis cell proliferation, migration, and survival. This drug shows promise for treating both treatment-naïve and resistant melanoma brain metastasis.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Melanoma frequently metastasizes to the brain, posing significant therapeutic challenges.
- Current treatments for melanoma brain metastasis face issues with therapy resistance and disease relapse.
- SRC family kinase (SFK) and Raf proto-oncogene, serine/threonine kinase (RAF) inhibitors represent a potential therapeutic avenue.
Purpose of the Study:
- To evaluate the efficacy of CCT196969 in preclinical models of melanoma brain metastasis.
- To investigate the impact of CCT196969 on melanoma cell proliferation, migration, and survival.
- To assess CCT196969's activity against BRAF inhibitor-resistant melanoma cell lines.
Main Methods:
- In vitro cell line assays were performed on multiple melanoma brain metastasis cell lines.
- Cell viability was assessed using IC50 dose calculations.
- Western blot analysis was used to examine key signaling pathway proteins (p-ERK, p-MEK, p-STAT3, STAT3).
Main Results:
- CCT196969 demonstrated significant inhibition of proliferation, migration, and survival across all tested cell lines.
- Viability IC50 doses ranged from 0.18 to 2.6 μM.
- Treatment led to decreased expression of phosphorylated ERK, MEK, and STAT3, along with total STAT3.
- CCT196969 effectively inhibited viability in BRAF inhibitor-resistant melanoma cell lines.
Conclusions:
- CCT196969 exhibits potent anti-cancer effects against melanoma brain metastasis cell lines in vitro.
- The drug's efficacy extends to BRAF inhibitor-resistant cell lines, suggesting broad applicability.
- Further in vivo studies are warranted to explore CCT196969's therapeutic potential in patients.
